Effects of PI3Kgamma inhibition using AS-605240 in acute myocardial infarction.
Seropian
Ignacio M
IM
Toldo
Stefano
S
Abbate
Antonio
A
Mezzaroma
Eleonora
E
Van Tassell
Benjamin W
BW
D000818:Animals; D002317:Cardiovascular Agents / Q000494:pharmacology*; D004195:Disease Models, Animal; D005838:Genotype; D051379:Mice; D018345:Mice, Knockout; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics / Q000503:physiopathology; D009206:Myocardium / Q000201:enzymology*; D018919:Neovascularization, Physiologic / Q000187:drug effects; D010641:Phenotype; D019869:Phosphatidylinositol 3-Kinases / Q000235:genetics / Q000378:metabolism; D000081082:Phosphoinositide-3 Kinase Inhibitors; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*; D011810:Quinoxalines / Q000494:pharmacology*; D045162:Thiazolidinediones / Q000494:pharmacology*; D016277:Ventricular Function, Left / Q000187:drug effects; D020257:Ventricular Remodeling / Q000187:drug effects
D002317:Cardiovascular Agents; D019869:Phosphatidylinositol 3-Kinases; D000081082:Phosphoinositide-3 Kinase Inhibitors; D047428:Protein Kinase Inhibitors; D011810:Quinoxalines; D045162:Thiazolidinediones; C505144:5-quinoxalin-6-ylmethylenethiazolidine-2,4-dione